Resource Center
Always with a focus on innovation, find resources that share our scientific experts passion and knowledge. Find case studies, info sheets, posters and more.
De-Risking FIH: Integrated Strategies for Rapid Proof-of-Concept
Download73 - 78 of 232 results
A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers
13 September 2022Non-Clinical vs Clinical: Risks & Considerations When Developing Modified Release Dosage Forms
1 September 2022Assessment of the Contribution of CYP2D6 to the Elimination of Idalopirdine as well as the Absolute Bioavailability Following Multiple Oral Dosing
26 August 2022CC-99677, A Novel, Oral, Selective Covalent MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production
23 August 2022CC-99677: A Novel, Oral, Selective Covalent MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production
23 August 2022ADME of opicapone in human healthy volunteers
16 June 2022Learn about Quotient Sciences' services
Where integrated CRDMO services bring therapies to life. Whether it's meeting your first-in-human milestone, confidently advancing your program to proof-of-concept, or providing a trusted supply of clinical trial materials or commercial drug product, learn about Quotient Sciences CRDMO offering and how we can support your next drug program.